Post-finasteride syndrome (PFS) has been claimed to occur in men who have taken oral finasteride to treat either hair loss or benign prostatic hyperplasia, independent of age, dosage, or indication. By definition, the condition is characterized by sexual dysfunction, somatic symptoms, and psychological disorders that persist after cessation of finasteride treatment. As yet, the condition is not recognized by the medical community, although individuals who suffer from PFS present with relatively homogenous symptoms. The concept of PFS has emerged from reports of non-dermatologists, neuroendocrinological research and reflections, and uncontrolled studies of low quality and with a strong bias selection, while a significant nocebo effect among patients informed about possible side effects of finasteride is recognized. There are no predictive factors for the risk of development of PFS. Nevertheless, it has been suggested that a patient history of preexisting mental health disorder, particularly depression, may put patients at an increased risk. We report the first case of PFS in a long-standing (over 20 years) dermatotrichological practice with frequent finasteride prescription observed in a 25-year-old male following dutasteride treatment for male androgenetic alopecia. There was circumstantial evidence that PFS may represent a delusional disorder of the somatic type, possibly on a background of a histrionic personality disorder, which would explain the refractoriness of the condition and a high degree of suggestibility.

1.
Gormley
GJ
,
Stoner
E
,
Bruskewitz
RC
,
Imperato-McGinley
J
,
Walsh
PC
,
McConnell
JD
, et al.;
The Finasteride Study Group
.
The effect of finasteride in men with benign prostatic hyperplasia
.
N Engl J Med
.
1992
Oct
;
327
(
17
):
1185
91
.
[PubMed]
0028-4793
2.
Traish
AM
,
Haider
KS
,
Doros
G
,
Haider
A
.
Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia
.
Horm Mol Biol Clin Investig
.
2015
Sep
;
23
(
3
):
85
96
.
[PubMed]
1868-1883
3.
Traish
AM
,
Hassani
J
,
Guay
AT
,
Zitzmann
M
,
Hansen
ML
.
Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients
.
J Sex Med
.
2011
Mar
;
8
(
3
):
872
84
.
[PubMed]
1743-6095
4.
Irwig
MS
,
Kolukula
S
.
Persistent sexual side effects of finasteride for male pattern hair loss
.
J Sex Med
.
2011
Jun
;
8
(
6
):
1747
53
.
[PubMed]
1743-6095
5.
Irwig
MS
.
Persistent sexual side effects of finasteride: could they be permanent?
J Sex Med
.
2012
Nov
;
9
(
11
):
2927
32
.
[PubMed]
1743-6095
6.
Di Loreto
C
,
La Marra
F
,
Mazzon
G
,
Belgrano
E
,
Trombetta
C
,
Cauci
S
.
Immunohistochemical evaluation of androgen receptor and nerve structure density in human prepuce from patients with persistent sexual side effects after finasteride use for androgenetic alopecia
.
PLoS One
.
2014
Jun
;
9
(
6
):
e100237
.
[PubMed]
1932-6203
7.
Ganzer
CA
,
Jacobs
AR
,
Iqbal
F
.
Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms
.
Am J Men Health
.
2015
May
;
9
(
3
):
222
8
.
[PubMed]
1557-9883
8.
Ali
AK
,
Heran
BS
,
Etminan
M
.
Persistent sexual dysfunction and suicidal ideation in young men treated with low-dose finasteride: a pharmacovigilance study
.
Pharmacotherapy
.
2015
Jul
;
35
(
7
):
687
95
.
[PubMed]
0277-0008
9.
Irwig
MS
.
Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects
.
J Clin Psychiatry
.
2012
Sep
;
73
(
9
):
1220
3
.
[PubMed]
0160-6689
10.
Altomare
G
,
Capella
GL
.
Depression circumstantially related to the administration of finasteride for androgenetic alopecia
.
J Dermatol
.
2002
Oct
;
29
(
10
):
665
9
.
[PubMed]
0385-2407
11.
Fertig
R
,
Shapiro
J
,
Bergfeld
W
,
Tosti
A.
Investigation of the Plausibility of 5-Alpha-Reductase Inhibitor Syndrome. Skin Appendage Disord.
2017
;2(3--4):120--129
12.
Tacklind
J
,
Fink
HA
,
Macdonald
R
,
Rutks
I
,
Wilt
TJ
.
Finasteride for benign prostatic hyperplasia
.
Cochrane Database Syst Rev
.
2010
Oct
;
2010
(
10
):
CD006015
.
[PubMed]
1469-493X
13.
Bratel
J
,
Haraldson
T
,
Meding
B
,
Yontchev
E
,
Ohman
SC
,
Ottosson
JO
.
Potential side effects of dental amalgam restorations. (I). An oral and medical investigation
.
Eur J Oral Sci
.
1997
Jun
;
105
(
3
):
234
43
.
[PubMed]
0909-8836
14.
Lindberg
NE
,
Lindberg
E
,
Larsson
G
.
Psychologic factors in the etiology of amalgam illness
.
Acta Odontol Scand
.
1994
Aug
;
52
(
4
):
219
28
.
[PubMed]
0001-6357
15.
Genuis
SJ
.
Chemical sensitivity: pathophysiology or pathopsychology?
Clin Ther
.
2013
May
;
35
(
5
):
572
7
.
[PubMed]
0149-2918
16.
Bornschein
S
,
Hausteiner
C
,
Römmelt
H
,
Nowak
D
,
Förstl
H
,
Zilker
T
.
Double-blind placebo-controlled provocation study in patients with subjective Multiple Chemical Sensitivity (MCS) and matched control subjects
.
Clin Toxicol (Phila)
.
2008
Jun
;
46
(
5
):
443
9
.
[PubMed]
1556-3650
17.
Bornschein
S
,
Förstl
H
,
Zilker
T
.
Idiopathic environmental intolerances (formerly multiple chemical sensitivity) psychiatric perspectives
.
J Intern Med
.
2001
Oct
;
250
(
4
):
309
21
.
[PubMed]
0954-6820
18.
Vulink
NC
.
Delusional Infestation: state of the Art
.
Acta Derm Venereol
.
2016
Aug
;
96
(
217
):
58
63
.
[PubMed]
1651-2057
19.
Bartholomew
R
,
Hassall
P
.
A Colorful History of Popular Delusions
.
Prometheus Books
;
2015
.ISBN: 1633881229.
20.
Mattelaer
JJ
,
Jilek
W
.
Koro—the psychological disappearance of the penis
.
J Sex Med
.
2007
Sep
;
4
(
5
):
1509
15
.
[PubMed]
1743-6095
21.
American Psychiatric Association
.
Diagnostic and Statistical Manual of Mental Disorders
. 5th ed., text revision.
Washington (DC)
:
American Psychiatric Association
;
2013
.
22.
Munro
A
.
Delusional disorder: paranoia and related illnesses.
Cambridge, UK: Cambridge University Press,
1999
. ISBN 0--521--58180-X.
23.
Bartholomew
RE
,
Wessely
S
.
Protean nature of mass sociogenic illness: from possessed nuns to chemical and biological terrorism fears
.
Br J Psychiatry
.
2002
Apr
;
180
(
04
):
300
6
.
[PubMed]
0007-1250
24.
American Psychiatric Association
.
Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR.
Chapter 16: Personality Disorders. American Psychiatric Publishing.
2000
25.
Maffei
C
,
Fossati
A
,
Rinaldi
F
,
Riva
E
.
Personality disorders and psychopathologic symptoms in patients with androgenetic alopecia
.
Arch Dermatol
.
1994
Jul
;
130
(
7
):
868
72
.
[PubMed]
0003-987X
26.
Trüeb
RM
. Psychopathological Disorders: In: Trüeb RM. The Difficult Hair Loss Patient. Guide to Successful Management of Alopecia and Related Conditions. Springer 2015: p. 168 Groopman, J. How Doctors Think. Boston, New York: Houghton Mifflin Company;
2007
27.
Mondaini
N
,
Gontero
P
,
Giubilei
G
,
Lombardi
G
,
Cai
T
,
Gavazzi
A
, et al.
Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon?
J Sex Med
.
2007
Nov
;
4
(
6
):
1708
12
.
[PubMed]
1743-6095
28.
Kaufman
KD
.
Androgen metabolism as it affects hair growth in androgenetic alopecia
.
Dermatol Clin
.
1996
Oct
;
14
(
4
):
697
711
.
[PubMed]
0733-8635
29.
Imperato-McGinley
J
,
Guerrero
L
,
Gautier
T
,
Peterson
RE
.
Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism
.
Science
.
1974
Dec
;
186
(
4170
):
1213
5
.
[PubMed]
0036-8075
30.
Kaufman
KD
,
Olsen
EA
,
Whiting
D
,
Savin
R
,
DeVillez
R
,
Bergfeld
W
, et al.;
Finasteride Male Pattern Hair Loss Study Group
.
Finasteride in the treatment of men with androgenetic alopecia
.
J Am Acad Dermatol
.
1998
Oct
;
39
(
4 Pt 1
):
578
89
.
[PubMed]
0190-9622
31.
Leyden
J
,
Dunlap
F
,
Miller
B
,
Winters
P
,
Lebwohl
M
,
Hecker
D
, et al.
Finasteride in the treatment of men with frontal male pattern hair loss
.
J Am Acad Dermatol
.
1999
Jun
;
40
(
6 Pt 1
):
930
7
.
[PubMed]
0190-9622
32.
Whiting
DA
,
Waldstreicher
J
,
Sanchez
M
,
Kaufman
KD
.
Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women
.
J Investig Dermatol Symp Proc
.
1999
Dec
;
4
(
3
):
282
4
.
[PubMed]
1087-0024
33.
Van Neste
D
,
Fuh
V
,
Sanchez-Pedreno
P
,
Lopez-Bran
E
,
Wolff
H
,
Whiting
D
, et al.
Finasteride increases anagen hair in men with androgenetic alopecia
.
Br J Dermatol
.
2000
Oct
;
143
(
4
):
804
10
.
[PubMed]
0007-0963
34.
Finasteride Male Pattern Hair Loss Study Group
.
Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia
.
Eur J Dermatol
.
2002
Jan-Feb
;
12
(
1
):
38
49
.
[PubMed]
1167-1122
35.
Kawashima
M
,
Hayashi
N
,
Igarashi
A
,
Kitahara
H
,
Maeguchi
M
,
Mizuno
A
, et al.
Finasteride in the treatment of Japanese men with male pattern hair loss
.
Eur J Dermatol
.
2004
Jul-Aug
;
14
(
4
):
247
54
.
[PubMed]
1167-1122
36.
Price
VH
,
Menefee
E
,
Sanchez
M
,
Kaufman
KD
.
Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results
.
J Am Acad Dermatol
.
2006
Jul
;
55
(
1
):
71
4
.
[PubMed]
0190-9622
37.
Kaufman
KD
,
Rotonda
J
,
Shah
AK
,
Meehan
AG
.
Long-term treatment with finasteride 1 mg decreases the likelihood of developing further visible hair loss in men with androgenetic alopecia (male pattern hair loss)
.
Eur J Dermatol
.
2008
Jul-Aug
;
18
(
4
):
400
6
.
[PubMed]
1167-1122
38.
Sato
A
,
Takeda
A
.
Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia
.
J Dermatol
.
2012
Jan
;
39
(
1
):
27
32
.
[PubMed]
0385-2407
39.
Olsen
EA
,
Hordinsky
M
,
Whiting
D
,
Stough
D
,
Hobbs
S
,
Ellis
ML
, et al.;
Dutasteride Alopecia Research Team
.
The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride
.
J Am Acad Dermatol
.
2006
Dec
;
55
(
6
):
1014
23
.
[PubMed]
0190-9622
40.
Eun
HC
,
Kwon
OS
,
Yeon
JH
,
Shin
HS
,
Kim
BY
,
Ro
BI
, et al.
Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study
.
J Am Acad Dermatol
.
2010
Aug
;
63
(
2
):
252
8
.
[PubMed]
0190-9622
41.
Gubelin Harcha
W
,
Barboza Martínez
J
,
Tsai
TF
,
Katsuoka
K
,
Kawashima
M
,
Tsuboi
R
, et al.
A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia
.
J Am Acad Dermatol
.
2014
Mar
;
70
(
3
):
489
498.e3
.
[PubMed]
0190-9622
42.
Jung
JY
,
Yeon
JH
,
Choi
JW
,
Kwon
SH
,
Kim
BJ
,
Youn
SW
, et al.
Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride
.
Int J Dermatol
.
2014
Nov
;
53
(
11
):
1351
7
.
[PubMed]
0011-9059
43.
Ganzer
CA
,
Jacobs
AR
.
Emotional consequences of finasteride: fool’s gold
.
Am J Men Health
.
2018
Jan
;
12
(
1
):
90
5
.
[PubMed]
1557-9883
44.
Trüeb
RM
. Tackling Adverse Effects. In:
Trüeb
RM
, editor
.
The Difficult Hair Loss Patient. Guide to Successful Management of Alopecia and Related Conditions
.
Springer
;
2015
. p.
181
.
45.
Basaria
S
,
Jasuja
R
,
Huang
G
,
Wharton
W
,
Pan
H
,
Pencina
K
, et al.
Characteristics of men who report persistent sexual symptoms after finasteride use for hair loss
.
J Clin Endocrinol Metab
.
2016
Dec
;
101
(
12
):
4669
80
.
[PubMed]
0021-972X
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.